Albireo Pharma Current Financial Leverage

ALBO
 Stock
  

USD 23.78  0.84  3.66%   

Albireo Pharma's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Albireo Pharma's financial risk is the risk to Albireo Pharma stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Please continue to the analysis of Albireo Pharma Fundamentals Over Time.
  
Albireo Pharma Issuance Repayment of Debt Securities is quite stable at the moment as compared to the past year. The company's current value of Issuance Repayment of Debt Securities is estimated at 11.77 Million. Debt to Equity Ratio is expected to rise to 0.07 this year, although the value of Total Debt will most likely fall to about 9.6 M.

Albireo Current Financial Burden

Albireo Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Albireo Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Albireo Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Albireo Pharma's stakeholders.

Asset vs Debt

Equity vs Debt

For most companies, including Albireo Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Albireo Pharma the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
non Currrent Assets Other
15.2 M
Price Book
4.55
other Assets
15.2 M
liabilities And Stockholders Equity
302.1 M
total Assets
302.1 M
Operating Margin
(2.15) 
Given the importance of Albireo Pharma's capital structure, the first step in the capital decision process is for the management of Albireo Pharma to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Albireo Pharma to issue bonds at a reasonable cost.

Albireo Pharma Financial Leverage Rating

Albireo Pharma bond ratings play a critical role in determining how much Albireo Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Albireo Pharma's borrowing costs.
Piotroski F Score
3  Frail
Beneish M Score

Albireo Pharma Debt to Cash Allocation

As Albireo Pharma follows its natural business cycle, the capital allocation decisions will not magically go away. Albireo Pharma's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Albireo Pharma has a current ratio of 4.4, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Albireo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Albireo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albireo Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albireo to invest in growth at high rates of return. When we think about Albireo Pharma's use of debt, we should always consider it together with cash and equity.

Albireo Pharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Albireo Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Albireo Pharma Debt Ratio

    
  2.95   
It seems most of the Albireo Pharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Albireo Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Albireo Pharma, which in turn will lower the firm's financial flexibility. Like all other financial ratios, an Albireo Pharma debt ratio should be compared their industry average or other competing firms.
Share Download
Share Download

Albireo Pharma Historical Liabilities

While analyzing the current debt level is an essential aspect of forecasting the current year budgeting needs of Albireo Pharma, understanding its historical liability is critical in projecting Albireo Pharma's future earnings, especially during periods of low and high inflation and deflation. Many analysts look at the trend in assets and liabilities and evaluate how Albireo Pharma uses its financing power over time.
In order to fund their growth, businesses such as Albireo Pharma widely use Financial Leverage. For most companies, financial capital is raised by issuing debt securities and by selling common stock. The debt and equity that make up Albireo Pharma's capital structure have many risks and return implications. Leverage is an investment strategy of using borrowed money to increase the potential return of an investment. Please note, the concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Understaning Albireo Pharma Use of Financial Leverage

Albireo Pharma financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Albireo Pharma's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Albireo Pharma assets, the company is considered highly leveraged. Understanding the composition and structure of overall Albireo Pharma debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it.
Last ReportedProjected for 2022
Total Debt10 M9.6 M
Debt Current3.5 M3.5 M
Debt Non Current10 M10 M
Issuance Repayment of Debt Securities10.9 M11.8 M
Long Term Debt to Equity 0.06  0.05 
Debt to Equity Ratio 0.06  0.07 
Please read more on our technical analysis page.

Albireo Pharma Investors Sentiment

The influence of Albireo Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Albireo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Albireo Pharma's public news can be used to forecast risks associated with investment in Albireo. The trend in average sentiment can be used to explain how an investor holding Albireo can time the market purely based on public headlines and social activities around Albireo Pharma. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Albireo Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Albireo Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Albireo Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Albireo Pharma.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-0.83EDSAEdesa Biotech Fiscal Year End 27th of December 2022 PairCorr
-0.63BEAMBeam TherapeuticsInc Normal TradingPairCorr
-0.59VZVerizon Communications TrendingPairCorr
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of Albireo Pharma Fundamentals Over Time. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
486.5 M
Quarterly Revenue Growth YOY
1.68
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.